Cellular assessment of muscle in COPD: Case studies of two males

International Journal of General Medicine

Volumn 2, Issue , 2009, Pages 227-242

  Green, Howard J ^a   Bombardier, Eric ^a   Burnett, Margaret E ^a   D'Arsigny, Christine L ^b   Iqbal, Sobia ^a   Webb, Katherine A ^b   Ouyang, Jing ^a   O'Donnell, Denis E ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Area; Capillarization; Enzymatic pathways; Excitation contraction processes; Fiber types; Glucose and monocarboxylate transporters; Metabolism; Vastus lateralis

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CARBOXYLIC ACID; CATION; CREATINE PHOSPHATE; CYTOCHROME C OXIDASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEXOKINASE; LACTIC ACID; PYRUVATE KINASE; SUCCINATE DEHYDROGENASE;

AGED; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENERGY TRANSFER; ENZYME ACTIVITY; EXPIRATORY RESERVE VOLUME; FORCED EXPIRATORY VOLUME; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; MALE; MUSCLE ATROPHY; MUSCLE METABOLISM; PHYSIOLOGY; REVIEW; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE;

EID: 77953408999     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/ijgm.s5981     Document Type: Review

References (67)

1. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Critical Care Med. 1995;152: 2021-2031.
2. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr. 2000;71:1033-1047.
3. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. 2001;2:216-224.
4. Troosters T, Gosselink R, Decramer M. Chronic obstructive pulmonary disease and chronic heart failure. J Cardiopul Rehab. 2004;24: 137-145.
5. 2+-sequestering properties in skeletal muscle in chronic obstructive lung disease. Am J Physiol. 2008;295:C350-C357.
6. Green HJ, Burnett M, D'Arsigny C, et al. Vastus lateralis Na+-K+-ATPase activity, protein, and isoform distribution in chronic obstructive pulmonary disease. Muscle Nerve. 2009;40:62-68.
7. Gosker HR, van Mameren H, van Dijk PJ, et al. Skeletal muscle fibretype shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19:617-625.
8. Gosker HR, Zeegers MP, Wouters EFM, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD Is associated with disease severity: a systemic review and meta-analysis. Thorax. 2007;62:944-949.
9. Maltais F, Sullivan MJ, Leblanc P, et al. Altered expression of myosin heavy chain in vastus lateralis muscle in patients with COPD. Eur Respir J. 1999;13:850-854.
10. Bottinelli R, Reggiani C. Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol. 2000;73:195-262.
11. Wouters EFM. Muscle wasting in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:4-5.
12. 2, glycolysis, energetics and intracellular PO2. J Appl Physiol. 1990;68:833-842.
13. Maltais F, Leblanc P, Whittom F, et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax. 2000;55:848-853.
14. Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med. 1996;153:288-293.
15. Allaire J, Maltais F, Doyon J-F, et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax. 2004;59:673-678.
16. Jakobsson P, Jorfeldt PL, Henriksson J. Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease. Am J Respir Critical Care Med. 1995;151: 374-377.
17. Sauleda J, Garcia-Palmer F, Wiesner RJ, et al. Cytochrome oxidase activity and mitochondrial gene expression in skeletal muscle of patients with chronic obstructive pulmonary disease. Am J Respir Critical Care Med. 1998;157:1413-1417.
18. Green HJ, Bombardier E, D'Arsigny C, O'Donnell D, Ouyang J. Organization of metabolic pathways on skeletal muscle of patients with chronic obstructive lung disease. Am J Physiol Regul Integr Comp Physiol. 2008;295:R935-R941.
19. Holloszy JO. A forty-year memoir of research on the regulation of glucose transport into muscle. Am J Physiol. 2003;284:E453-E467.
20. Juel C, Halestrap AP. Lactate transport in skeletal muscle-role of regulation of monocarboxylate transporter. J Physiol. 1999;517: 633-642.
21. Green HJ, Burnett M, D'Arsigny C, et al. Altered metabolic and transporter characteristics in vastus lateralis in chronic obstructive pulmonary disease. J Appl Physiol. 2008;105:879-896.
22. Pette D, Staron RS. Mammalian skeletal muscle fiber type transitions. Int Rev Cytol. 1997;170:143-223.
23. Couillard A, Préfaut C. From muscle disease to myopathy to COPD: Potential contribution of oxidative stress. Eur Respir J. 2005;26: 703-709.
24. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31:492-501.
25. Mathieu-Costello O. Comparative aspects of muscle capillary supply. Annu Rev Physiol. 1993;55:503-526.
26. Green HJ, Burnett M, D'Arsigny C, et al. Muscle fiber type characteristics in females with chronic obstructive pulmonary disease. preliminary study. J Mol Histol. 2009;40:41-51.
27. Bergström J. Muscle electrolytes in man. Scand J Clin Lab Invest. 1962;68(Suppl):1-110.
28. Staron RS, Pette D. The continuum of pure and hybrid myosin heavy chain-based fibre types in rat skeletal muscle. Histochemistry. 1993;100:149-153.
29. Ennion S, Periera JS, Sargent AJ, Young A, Goldspink G. Characterization of human skeletal muscle fibres according to the myosin heavy chain they express. J Muscle Res Cell Motil. 1995;16:35-43.
30. Parsons DB, McIntyre K, Schulz W, Stray-Gunderson J. Capillarity of elite cross-country skiiers. a lectin (Ulex Europeaus 1) marker. Scand J Med Sci Sports. 1993;3:89-98.
31. Pette D. Microphotometric measurement of initial reaction rates in quantitative enzyme histochemistry in situ. Histochem J. 1981;13: 319-327.
32. Van Der Laarse WJ, Van Nocrt P, Simonides WS, et al. Histochemistry of sarcoplasmic reticulum Ca-ATPase using dysprosiom as capturing reagent. Histocheml J. 1995;27:702-714.
33. 2+-ATPase Activity. Am J Cardiol. 2000;85:1498-1500.
34. Pette D, Dölken G. Some aspects of regulation of enzyme levels in muscle energy-supplying metabolism. Adv Enz Reg. 1975;13:355-378.
35. Henriksson JM, Chi MY, Hintz CS, et al. Chronic stimulation of mammalian muscle: changes in enzymes of six metabolic pathways. Am J Physiol. 1986;251:C614-C632.
36. Green HJ, Bombardier E, Duhamel TA, et al. Acute reductions in muscle mitochondrial and cytosolic enzyme activities during heavy intermittent exercise. J Appl Physiol. 2008;104:931-937.
37. Schacterle GR, Pollock RL. A simplified method for the quantitative assay of small amounts of protein in biologic material. Anal Biochem. 1973;51:654-655.
38. Ingebretson DC, Bakken AM, Segadal L, Farstad M. Determination of adenine nucleotides and inosine in human myocardium by ion pair reversed phase high performance liquid chromatography. J Chromatogr. 1982;242:119-126.
39. Green HJ, Duhamel T, Holloway GP, et al. Rapid upregulation of GLUT4 and MCT4 expression during sixteen hours of heavy intermittent cycle exercise. Am J Physiol. 2008;294:R594-R600.
40. +-dependent 3-O-methylfluorescein phosphatase activity. Biochem Biophys Acta. 1984;770:203-209.
41. Fraser SF, McKenna MJ. Measurement of Na+-K+-ATPase activity in human skeletal muscle. Anal Biochem. 1998;258:63-67.
42. 3h-ouabain binding sites in biopsies of human skeletal muscle. Scand J Clin Lab Invest. 1984;44:509-518.
43. Green HJ, Duhamel TA, Holloway GP, et al. Muscle Na+-K+-ATPase response during 16 hours of heavy intermittent cycle exercise. Am J Physiol. 2007;293:E523-E530.
44. 2+-ATPase activity in muscle homogenates. Anal Biochem. 1990;191:321-331.
45. Duhamel TA, Stewart RD, Tupling AR, Ouyang J, Green HJ. Muscle sarcoplasmic reticulum calcium regulation during consecutive days of exercise and recovery. J Appl Physiol. 2007;103:1212-1220.
46. 2+-ATPase of sarcoplasmic reticulum. J Biol Chem. 1989;264:17816-17823.
47. MacLennan DH, Abu-Abed M, Kang C. Structure-function relationships in Ca2+-cycling proteins. J Mol Cell Cardiol. 2002;34:897-918.
48. Staron RS. Human skeletal muscle fibre types: delineation, development and distribution. Can J Appl Physiol. 1997;22:307-327.
49. McComas AJ. Skeletal muscle Form and function. Champaign, IL: Human Kinetics; 1996.
50. Pette D, Vrbova C. What does chronic electrical stimulation teach us about muscle plasticity? Muscle Nerve. 1999;22:666-677.
51. Green HJ, Sutton JR. Altitude and skeletal muscle. In: Hornbein TF, Schoene RB, editors. Lung Biology in Health and Disease. New York, NY: Marcel Dekker Inc. 2000;443-492.
52. Gosker HR, Engeler MPKJ, van Mameren H, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive lung disease. Am J Clin Nutr. 2002;76:113-119.
53. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis in patients with chronic obstructive pulmonary disease. Med Sci Sports. 1998;30:1467-1474.
54. Maltais F, Leblanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Critical Care Med. 1996;154:442-447.
55. 2 with small muscle mass exercise. Am J Respir Critical Care Med. 2004;169:89-96.
56. Brooks SPJ, Storey KB. Where Is the glycolytic complex? A critical evaluation of present data from muscle tissue. FEBS Lett. 1991;276: 135-138.
57. Juel C. Training-induced changes in membrane transport proteins of human skeletal muscle. Eur J Appl Physiol. 2006;96:627-635.
58. + Pump regulation and skeletal muscle contractility. Physiol Rev. 2003;83:1269-1324.
59. +-ATPase following a 21 day expedition to 6,194m. J Appl Physiol. 2000;88:634-640.
60. Gosselin N, Matecki S, Poulain M. Electrophysiologic changes during exercise testing in patients with chronic obstructive pulmonary disease. Muscle Nerve. 2003;27:170-179.
61. Berchtold MW, Brinkmeier H, Müntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity and disease. Physiol Rev. 2000;80:1216-1265.
62. 2+-binding and translocation domain of SERCA 1: Physiological correlates in brody disease. Acta Physiol Scand. 2002;163(Suppl 643):55-67.
63. Morlà MM, Iglesias A, Sauleda J, et al. Reduced expression of the sarcoplasmic calcium pump SERCA2 in skeletal muscle from patients with chronic obstructive pulmonary disease and low body weight. Arch Bronconeumol. 2007;43:4-8.
64. Allen DG, Lamb AG, Westerblad H. Impaired calcium release during fatigue. J Appl Physiol. 2008;104:296-305.
65. Meyer RA, Foley JM. Cellular processes integrating the metabolic response to exercise. In: Rowell L, Shephard J, editors. Handbook of Physiology. Exercise: Regulation and Integration of Multiple Systems. New York, NY: Oxford University Press. 1996;841-869.
66. Jakobsson P, Jorfeldt PL, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease, with and without chronic respiratory failure. Eur Respir J. 1990;3:192-196.
67. Fiaccadori E, Del Canale S, Vitali P, et al. Skeletal muscle energetics, and acid-base equilibrium and lactate metabolism in patients with severe hypercapnia and hypoxemia. Chest. 2008;92:883-887.